SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM).

被引：0

作者：

Garland, Linda L.

Ou, Sai-Hong

Moon, James

Mack, Philip C.

Testa, Joseph

Tsao, Anne S.

Wozniak, Antoinette J.

Gandara, David R.

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[2] UC Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Orange, CA USA

[3] Southwest Oncol Grp Stat Ctr, Seattle, WA USA

[4] Univ Calif Davis, Sacramento, CA 95817 USA

[5] Fox Chase Canc Ctr, Buckingham, PA USA

[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[7] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[8] UC Davis Canc Ctr, Div Hematol & Oncol, Sacramento, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7083

引用

页数：1

共 50 条

[41] Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals
O'Reilly, Terence
McSheehy, Paul M. J.
TRANSLATIONAL ONCOLOGY, 2010, 3 (02): : 65 - 79
[42] Activity of mTOR-Inhibitor Rad001 (everolimus) in differentiated and anaplastic thyroid cancer cell lines
Behlendorf, T.
Voigt, W.
Mueller, T.
Jordan, K.
Arnold, D.
Schmoll, H.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43] Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Yee, Karen W. L.
Zeng, Zhihong
Konopleva, Marina
Verstovsek, Srdan
Ravandi, Farhad
Ferrajoli, Alessandra
Thomas, Deborah
Wierda, William
Apostolidou, Efrosyni
Albitar, Maher
O'Brien, Susan
Andreeff, Michael
Giles, Francis J.
CLINICAL CANCER RESEARCH, 2006, 12 (17) : 5165 - 5173
[44] The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
Ma, Brigette B. Y.
Lui, Vivian W. Y.
Hui, Edwin P.
Lau, Cecilia P. Y.
Ho, Kakiu
Ng, Margaret H. L.
Cheng, S. H.
Tsao, Sai-Wah
Chan, Anthony T. C.
INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 413 - 420
[45] A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
Amato, Robert J.
Jac, Jaroslaw
Giessinger, Sarah
Saxena, Somyata
Willis, James P.
CANCER, 2009, 115 (11) : 2438 - 2446
[46] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
Kotsakis, A. P.
Tarhini, A.
Petro, D.
Flaugh, R.
Vallabhaneni, G.
Belani, C. P.
Friedland, D.
Argiris, A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[47] Phase II study of RAD001 (Everolimus) in previously treated small cell lung cancer (SCLC)
Owonikoko, T. K.
Stoller, R. G.
Petro, D.
Flaugh, R.
Hershberger, P. A.
Belani, C. P.
Argiris, A. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[48] mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Lane, Heidi A.
Wood, Jeanette M.
McSheehy, Paul M. J.
Allegrini, Peter R.
Boulay, Anne
Brueggen, Joseph
Littlewood-Evans, Amanda
Maira, Sauveur-Michel
Martiny-Baron, Georg
Schnell, Christian R.
Sini, Patrizia
O'Reilly, Terence
CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1612 - 1622
[49] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
Whorf, R. C.
Hainsworth, J. D.
Spigel, D. R.
Yardley, D. A.
Burris, H. A., III
Waterhouse, D. M.
Vazquez, E. R.
Greco, F. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[50] Phase II study of RAD001 (everolimus) in previously treated small cell lung cancer (SCLC)
Kotsakis, Athanasios
Tarhini, Ahmad
Petro, Daniel
Flaugh, Rick
Vallabhaneni, Geetha
Belani, Chandra
Friedland, David
Argiris, Athanassios
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S464 - S464

← 1 2 3 4 5 →